BlossomHill Therapeutics, Inc. (BLSM)

NASDAQ: BLSM · Real-Time Price · USD

16.35

+0.11 (0.68%)

At close: Aug 13, 2026, 4:00 PM EDT

17.24

+0.89 (5.44%)

After-hours: Aug 13, 2026, 7:39 PM EDT

BlossomHill Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	8.21	7.89	4.59
Research & Development	66.47	56.14	31.81
Operating Expenses	74.68	64.02	36.4
Operating Income	-74.68	-64.02	-36.4
Interest & Investment Income	3.61	3.48	5.71
Currency Exchange Gain (Loss)	-0.01	-0.01	-
Pretax Income	-71.09	-60.56	-30.7
Net Income	-71.09	-60.56	-30.7
Net Income to Common	-71.09	-60.56	-30.7
Net Income Growth	-	-	-
Shares Outstanding (Basic)	2	2	2
Shares Outstanding (Diluted)	2	2	2
Shares Change	-	6.47%	-
EPS (Basic)	-28.59	-24.83	-13.40
EPS (Diluted)	-28.59	-24.83	-13.40
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-57.56	-47.99	-31.51
Free Cash Flow Per Share	-23.15	-19.68	-13.76
EBITDA	-74.2	-63.58	-36.05
D&A For EBITDA	0.48	0.44	0.35
EBIT	-74.68	-64.02	-36.4

SEC Filings: 10-K · 10-Q